^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Apply
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (NCT07472517)
    Phase 3
    Boehringer Ingelheim
    Not yet recruiting
    Last update posted :
    03/16/2026
    Initiation :
    04/10/2026
    Primary completion :
    09/10/2028
    Completion :
    04/16/2029
    DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) (NCT07190833)
    Phase 1
    Bionoxx Inc.
    Not yet recruiting
    Last update posted :
    09/24/2025
    Initiation :
    11/01/2025
    Primary completion :
    12/01/2028
    Completion :
    12/01/2030
    PD-L1
    |
    Tecentriq (atezolizumab) • hydroxyurea
    Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (NCT07190027)
    Phase 1/2
    First Affiliated Hospital of Wenzhou Medical Un...
    Not yet recruiting
    Last update posted :
    09/24/2025
    Initiation :
    11/01/2025
    Primary completion :
    11/01/2025
    Completion :
    11/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (NCT07170592)
    Phase 1
    Bionoxx Inc.
    Not yet recruiting
    Last update posted :
    09/12/2025
    Initiation :
    12/01/2025
    Primary completion :
    12/01/2028
    Completion :
    12/01/2030
    PD-L1
    |
    Tecentriq (atezolizumab) • hydroxyurea
    SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma (NCT07049848)
    Phase 2
    M.D. Anderson Cancer Center
    Not yet recruiting
    Last update posted :
    07/03/2025
    Initiation :
    12/01/2025
    Primary completion :
    01/01/2028
    Completion :
    01/01/2030
    PD-L1
    |
    Tecentriq (atezolizumab) • doxorubicin hydrochloride
    Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma (ARTEMIDE-HCC01) (NCT06921785)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    05/31/2025
    Initiation :
    05/06/2025
    Primary completion :
    03/16/2029
    Completion :
    03/15/2030
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)
    Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (ECOG-ACRIN EA3202) (NCT05063552)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2023
    Primary completion :
    12/15/2027
    Completion :
    12/15/2027
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/16/2017
    Primary completion :
    04/02/2025
    Completion :
    04/02/2025
    MLH1 • MSH6 • MSH2 • CD4
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma (NCT04458922)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2020
    Primary completion :
    11/28/2022
    Completion :
    12/13/2025
    EWSR1 • ATF1 • CREB1
    |
    Tecentriq (atezolizumab)
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung) (NCT03337698)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/27/2017
    Primary completion :
    09/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)